Abstract 1482P
Background
More than 80% patients of Carcinoma Gall bladder (Ca GB) present with unresectable or disseminated disease. In these patients jaundice can be very distressing leading to poor quality of life (QOL) PTBD has been advocated to palliate this but, its impact on QOL has not been adequately studied.
Methods
Prospective observational study over two years included patients of proven unresectable/disseminated Ca GB presenting with jaundice. Pre-procedure parameters were recorded and PTBD done. Quality of Life (QOL) was assessed by EORTC QLQ-C30 and BIL-21 scores prior to the treatment and after 1- month. Post procedure complications were reported. Follow up was done at 1,3 and 6 months.
Results
Study included 43 patients of unresectable/disseminated Ca GB. Median age was 52 years with 74% females. 26 patients underwent unilateral (U/L) and 17 bilateral (B/L) PTBD. 4 patients needed B/L PTBD for inadequate bilirubin fall at 4 weeks. Mean serum bilirubin was 18.3 ± 7.3 mg/dl, albumin was 2.9 ± 0.5 mg/dl and INR was 1.7 ± 1.2. Commonest indication for PTBD was pruritus (65%) and only 12% patients had cholangitis. Bilirubin level at 1 week and 1 month was 15mg/dl and 7.1 mg/dl respectively(p=0.0002). Unfortunately, EORTC QLQ-C30 QOL scores showed decline in all aspects at 1 months and 3 months. Even in BIL-21 scores although there was improvement in Jaundice scale those with anxiety, pain and side effects had decline. Most patients had morbidity related to either slippage of PTBD or peri-tubal leakage. Also, inevitability of disease progression due to lack of treatment caused significant anxiety. 4 patients expired within 30 days due to cholangitis. Survival at 1-, 3- and 6- months was 60%, 23% and 7% respectively with median survival of 38 days.
Conclusions
Although jaundice is a fairly debilitating symptom in patients with unresectable Ca GB, palliation in form of PTBD may not always lead to improvement of QOL. Psychological counselling and proper guidance in terms of care of drains as well proper pain management is imperative to provide these terminally ill patients with best supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10